AMGN compared with INTS: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

INTSIntensity Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

INTSIntensity Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

AMGNAmgen Inc

478.34· pre 481.17· delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

INTSIntensity Therapeutics, Inc.

3.38· pre 3.30· delayed

Pre-marketNov 5 '26delayed

Mkt cap$11.0MRevenue—Revenue—

Compare

Pre-marketNov 5 '26delayed

AMGNAmgen Inc

INTSIntensity Therapeutics, Inc.

478.34pre 481.17delayed

Price

3.38pre 3.30delayed

$258.8B

Mkt cap

$11.0M

Q3 FY26$10.4B

Revenue

—

FY25$36.8B

Revenue

—

AMGN478.34vsINTS3.38Pre-marketNov 5 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

AMGN, solidINTS, dashed

Supply-chain overlap

Revenue flow

INTS: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only INTS 2

MRKMercksupplier

BMYBristol-Myers Squibbsupplier

Role chip = supplier or customerSource: SEC EDGAR